http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2741596-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fdbaf314c3b77900972981843ce5ed0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D235-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2017-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c89ca9baee29563741d74e1ab811b31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14fe5841ef3d07b97d507cb21e232415 |
| publicationDate | 2021-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2741596-C2 |
| titleOfInvention | Urea compound, a method for production thereof and medical use thereof |
| abstract | FIELD: pharmaceuticals.SUBSTANCE: invention relates to a compound of general formula (I) or pharmaceutically acceptable salts thereof, where groupis selected from the following structure:, each of R51and R52is independently selected from a group consisting of hydrogen; W and Z are each independently selected from N and C-BR1; in the absence of R1, B are identical or different and each is independently selected from a group consisting of hydrogen, halogen, C1-C6alkyl, wherein said C1-C6alkyl optionally further substituted with one or more groups Q; in the presence of R1, B are identical or different and each is independently selected from a group consisting of -O- and -NR4-; and R1are identical or different and are each independently selected from the group consisting of hydrogen, C1-C6alkyl, heteroaryl, which is a heteroaromatic system containing 1 to 2 heteroatoms, 5 to 6 ring atoms, where the heteroatom is selected from sulfur and nitrogen, -RuORx, -RuC(O)ORx, -RuN(Ry)(Rz), -C(O)N(Ry)(Rz); said alkyl and said heteroaryl is optionally further substituted with one, two or three groups selected from the group consisting of halogen, cyano, hydroxy, C1-C6alkyl, C1-C6alkoxy, C1-C6hydroxyalkoxy, -C(O)NHCH3, heterocyclyl, which is a saturated monocyclic hydrocarbon group containing from 4 to 6 ring atoms, 1 or 2 of which can be replaced with oxygen and/or nitrogen, halophenyl, C3-C6cycloalkyl-tetrazolyl; R4is selected from a group consisting of C1-C6alkyl, or R4and R1together with the nitrogen atom to which they are attached, form piperazinyl, which is further substituted with one group selected from a group consisting of C1-C6alkyl; R2is hydrogen, G is selected from the group:, which is optionally further substituted with one or two groups selected from a group, consisting of C1-C6alkyl, amino, -C(O)-CH=CH2, C3-C6cycloalkyl, phenyl and pyridinyl; wherein said C1-C6alkyl or phenyl can be further substituted with one or three groups selected from a group consisting of halogen, hydroxy, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, -C(O)OC2H5; R3is selected from Q group; Ruis selected from a bond or C1-C6alkylene; Rxis selected from C1-C6alkyl; Ryand Rzare each independently selected from a group consisting of C1-C6alkyl; or Ryand Rztogether with the nitrogen atom to which they are attached form a heterocyclyl group containing from 6 to 7 ring atoms, which additionally contains 1 heteroatom selected from nitrogen or oxygen, and heterocyclyl group optionally further substituted with one group, selected from the group consisting of C1-C6alkyl; Q is selected from a group consisting of hydrogen and halogen. Invention also relates to methods of producing said compounds of formula (I).EFFECT: technical result is obtaining novel compounds which can be used in medicine as a tyrosine protein kinase FLT3 inhibitor for preventing and/or treating a malignant growth.12 cl, 11 tbl, 134 ex |
| priorityDate | 2016-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1492.